On January 6, 2023 Biosortia Microbiomics, the small molecule drug discovery platform and the only company practicing microbiome mining reported that it is presenting at Biotech ShowcaseTM 2023, taking place on January 9-11 in San Francisco, CA (Press release, Biosortia Pharmaceuticals, JAN 6, 2023, View Source [SID1234625996]). This year, registered attendees can view Biosortia Microbiomics’ presentation live, and with 24/7 on-demand access, attendees can also view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Ross Youngs, CEO, and Founder of Biosortia Microbiomics will be presenting on January 10 at 10:00 am PT at Franciscan A (ballroom level) at the event. In his session, Ross will explore the current problems with drug costs and drug discovery and educate the audience about industrial-scale microbiome mining and how it fits into the solution.
Ross will discuss how in just the past ten years, new drug costs have increased by 300% with minimal progress in finding new cures or treatments. And although small molecules are 90% of drugs on the shelf, the most sought-after drug-like small molecules can’t be obtained by indirect methods. Ross will also share how Biosortia’s technology, which is backed by the U.S. Air Force Research Laboratory, ARPA-E, DARPA and NIH are proven for obtaining nature’s drug-like small molecules, which were previously inaccessible, for treatments and cures.
"The capabilities and potential impact of Biosortia’s technology on the drug discovery industry is what motivates me and my team," says Youngs. "We’ve received incredible support through funding from major organizations that allowed us to prove the effectiveness of our technology. The next step for us is to continue raising funds in order to put the technology to work and collaborate with researchers and academia to accelerate discovery in critical life science areas."
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.
"We are delighted that Biosortia Microbiomics will be joining us in San Francisco and presenting at Biotech Showcase this year," said Sara Demy, CEO of Demy-Colton. "Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery."